Danske: Shire is on the M&A prowl
Flemming Ørnskov’s outlook for the future has probably not become any gloomier following Shire’s botched merger with AbbVie. The Irish company will now look around for M&A targets of its own, but there could be obstacles along the way.
BY STEFAN SINGH KAILAY
According to Claus Henrik Johansen, senior portfolio manager in Danske Capital, the biggest topic for debate during the month of October has been the US drug giant AbbVies decision not to go ahead with a proposed merger with Shire. But the Irish company has not been weakened by the experience.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Santaris expands Shire deal
For abonnenter
Political unrest could accelerate acquisitions
For abonnenter
Shire is talking to Danish companies
For abonnenter
